Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMUNO BCG Moreau RJ in High-Risk Non-Muscle Invasive Bladder Cancer
NCT03982797Phase 2Unknown
- Sponsor
- Biofabri
- Start
- May 2019
- Primary completion
- Apr 2021
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Imuno BCG Moreau RJ in bladder cancer, sponsored by Biofabri. Status: unknown.
02
Drugs
Imuno BCG Moreau RJ
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03982797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982797.